ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08945
-0,01%
Bitcoin
67.103,15
0,03%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Neurocrine Biosciences Inc (NBIX)

  7. Neurocrine Biosciences Inc (NBIX) News

NBIX

Neurocrine Biosciences (NBIX)

Neurocrine Biosciences Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:NBIX
DatumZeitQuelleÜberschriftSymbolFirma
17/05/202422h32Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
17/05/202422h31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
17/05/202422h31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
16/05/202422h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
16/05/202422h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
14/05/202422h23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
14/05/202422h23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
14/05/202414h30PR Newswire (US)Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024NASDAQ:NBIXNeurocrine Biosciences Inc
09/05/202415h45PR Newswire (US)Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024NASDAQ:NBIXNeurocrine Biosciences Inc
09/05/202414h30PR Newswire (US)Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy AdultsNASDAQ:NBIXNeurocrine Biosciences Inc
08/05/202422h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
08/05/202414h30PR Newswire (US)Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy AdultsNASDAQ:NBIXNeurocrine Biosciences Inc
07/05/202422h15PR Newswire (US)Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care ConferenceNASDAQ:NBIXNeurocrine Biosciences Inc
07/05/202414h30PR Newswire (US)Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024NASDAQ:NBIXNeurocrine Biosciences Inc
06/05/202414h30PR Newswire (US)Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and MonitoringNASDAQ:NBIXNeurocrine Biosciences Inc
03/05/202419h15PR Newswire (US)Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024NASDAQ:NBIXNeurocrine Biosciences Inc
01/05/202413h00PR Newswire (US)Neurocrine Biosciences Reports First Quarter 2024 Financial ResultsNASDAQ:NBIXNeurocrine Biosciences Inc
30/04/202423h12PR Newswire (US)Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) CapsulesNASDAQ:NBIXNeurocrine Biosciences Inc
24/04/202414h30PR Newswire (US)Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia CommunityNASDAQ:NBIXNeurocrine Biosciences Inc
23/04/202413h00PR Newswire (US)Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive DisorderNASDAQ:NBIXNeurocrine Biosciences Inc
16/04/202422h01GlobeNewswire Inc.Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF PeptidesNASDAQ:NBIXNeurocrine Biosciences Inc
10/04/202422h01PR Newswire (US)Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial ResultsNASDAQ:NBIXNeurocrine Biosciences Inc
03/04/202414h30PR Newswire (US)Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive DisorderNASDAQ:NBIXNeurocrine Biosciences Inc
28/03/202413h30PR Newswire (US)Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy AdultsNASDAQ:NBIXNeurocrine Biosciences Inc
11/03/202421h01PR Newswire (US)Neurocrine Biosciences to Participate at Virtual Investor Conferences in MarchNASDAQ:NBIXNeurocrine Biosciences Inc
08/03/202422h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
08/03/202422h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
01/03/202401h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
01/03/202400h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
01/03/202400h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:NBIX

Kürzlich von Ihnen besucht

BIT
P1VZ89
NLBNPIT1VZ89 20351221 32...
USOTC
MACE
Mace Security (QB)
DBI
0J4Z
VVSTOXX MAY 2024
TSXV
XOX.P
Planet X Capital
BITMOT
891706
Ifc Zc St30 Rub
COIN
EMIRGBTC
KUCN
AURAUSDT
Aura
COIN
HVIUST
Hungarian Vizsla Inu
LSE
RGO
Riverfort Global Opportu...
LSE
LSAA
Life Settlement Assets
DGFX
HIVEUSDT
Hive
LSE
MIX
Mobeus Income & Growth Vct
BIT
P1VEI2
NLBNPIT1VEI2 20991231 72...
BIT
F11483
Vontobel Financial Produ...
NASDAQI
OMXS30ETHICGI
OMX GES OMXS30 Ethical G...
BIT
P1Z8H0
NLBNPIT1Z8H0 20240620 5200
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten